BioCarier® Technology Platform to Accelerate RapaGlue™ Drug Development
-Chengdu Manufacturing Facility Successfully Completes FDA cGMP Inspection
ZennovaPharmaceuticalsrecentlyannouncedsignificantadvancementsinitsinnovativeleukemiadrug,Zenno-10,basedonitsproprietarysingle-nanodrugdeliveryplatform,BioCarier®.Thelatesthumanclinicaltrialshaved...
Zennova PharmaceuticalrecentlyannouncedapartnershipwithInnogenix,aleadingpharmaceuticalcompanydintheUnitedStates.ThecollaborationgrantsZennovavariesofrightstoaccesstencutting-edgeRxproductsdevel...
Zennova Pharmaceutical (Chengdu) Co., Ltd. (referred to as "Zennova") has successfully achieved the esteemed status of "The National High-Tech Enterprises" in 2022.
Zennova Pharmaceutical has successfully completed its Series A fund raising of tens of millions of RMB from Dyee Capital, the lead investor, and Shining Capital,the co-investor, on August 23, 2021.